Vafa Shahabi
1. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.Wallecha A, Carroll KD, Maciag PC, ...Rivera S, Shahabi V, Paterson Y
Adv Appl Microbiol. 2009. 66: 1-27
2. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.
Seavey MM, Pan ZK, Maciag PC, ...Wallecha A, Rivera S, Paterson Y, Shahabi V
Clin Cancer Res. 2009 Feb 1. 15(3): 924-32
3. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.
Wallecha A, Maciag PC, Rivera S, ...Paterson Y, Shahabi V
Clin Vaccine Immunol. 2009 Jan. 16(1): 96-103
4. Development of a Listeria monocytogenes based vaccine against prostate cancer.
Shahabi V, Reyes-Reyes M, Wallecha A, ...Rivera S, Paterson Y, Maciag P
Cancer Immunol Immunother. 2008 Sep. 57(9): 1301-13
5. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
Sewell DA, Shahabi V, Gunn GR 3rd, ...Pan ZK, Dominiecki ME, Paterson Y
Cancer Res. 2004 Dec 15. 64(24): 8821-5
Pages:
1
